6YQP
Crystal structure of the first bromodomain of human BRD4 in complex with the dual inhibitor TW22
Summary for 6YQP
Entry DOI | 10.2210/pdb6yqp/pdb |
Descriptor | Bromodomain-containing protein 4, 1,2-ETHANEDIOL, (~{E})-3-[4-[[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6 ),4,7,10,12-pentaen-9-yl]ethanoylamino]methyl]phenyl]-~{N}-oxidanyl-prop-2-enamide, ... (4 entities in total) |
Functional Keywords | bromodomain, brd4(bd1), dual bromodomain hdac inhibitor, structural genomics consortium, sgc, gene regulation |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 15860.66 |
Authors | Joerger, A.C.,Balourdas, D.I.,Weiser, T.,Chatterjee, D.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2020-04-17, release date: 2020-05-27, Last modification date: 2024-01-24) |
Primary citation | Zhang, X.,Zegar, T.,Weiser, T.,Hamdan, F.H.,Berger, B.T.,Lucas, R.,Balourdas, D.I.,Ladigan, S.,Cheung, P.F.,Liffers, S.T.,Trajkovic-Arsic, M.,Scheffler, B.,Joerger, A.C.,Hahn, S.A.,Johnsen, S.A.,Knapp, S.,Siveke, J.T. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Int.J.Cancer, 147:2847-2861, 2020 Cited by PubMed: 32599645DOI: 10.1002/ijc.33137 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.25 Å) |
Structure validation
Download full validation report